Navigation

Gout (tophaceous, severe debilitating, chronic) - pegloticase [ID521]

Pegloticase for treating severe debilitating chronic tophaceous gout

Status: History
Expected date of issue: June 2013
Referral date: February 2012
Process: STA
Notes:

Scoped as part of Batch 21

Topic area:
 

NICE project team

Executive Lead: TBC
Technical Lead: Anwar Jilani
Communications manager: Tonya Gillis
Project manager: Lori Farrar
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 10 August 2012
1st appraisal committee meeting: 13 November 2012
2nd appraisal committee meeting 13 March 2013
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Savient Pharmaceuticals (pegloticase)

Patient/carer groups

  • UK Gout Society

Professional groups

  • British Society for Rheumatology
  • Primary Care Rheumatology Society
  • Royal College of Nursing
  • Royal College of Pathologists
  • Royal College of Physicians

Others

  • Department of Health
  • Welsh Government

General

  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare Improvement Scotland

Comparator manufacturer(s)

  • A. Menarini Pharma  (febuxostat)

Relevant research groups

  • Arthritis Research UK

Evidence Review Group

  • Warwick Evidence
  • National Institute for Health Research Health Technology Assessment Programme

Associated guideline groups

  • None

Associated public health groups

  • None

Top


 

Project history

Date Update
27 December 2012 Following a regulatory update from the manufacturer, this appraisal was paused and the second Committee meeting scheduled for 13 February 2013 has been cancelled. A second Committee meeting date will be confirmed in early 2013.
1 June 2012 Following a regulatory update from the manufacturer the Appraisal Committee meeting scheduled for 25 September has been cancelled.  The Appraisal Committee discussion will now take place on 13 November.  The Committee assigned to this appraisal has changed from Committee D to Committee C.
Top


 

Key documents

This page was last updated: 24 June 2013

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.